Randomized trial shows improved exercise capacity in patients with pulmonary hypertension, suggesting inhaled treprostinil is beneficial.
In patients with pulmonary hypertension due to interstitial lung disease, inhaled treprostinil improved exercise capacity from baseline, assessed with the use of a 6-minute walk test, as compared with placebo. (Funded by United Therapeutics; INCREASE ClinicalTrials.gov number, NCT02630316.).
No takes yet. Share an insight, caveat, or question.
Waxman et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: